title: [Anti-TNF alpha therapy: a risk factor for legionella infection].
authors.forename: J C
authors.initials: JC
authors.lastname: Lagier
authors.forename: D
authors.initials: D
authors.lastname: Andriamanantena
authors.forename: J
authors.initials: J
authors.lastname: Damiano
authors.forename: J M
authors.initials: JM
authors.lastname: Dot
authors.forename: B
authors.initials: B
authors.lastname: Chaudier
authors.forename: J
authors.initials: J
authors.lastname: Margery
mesh_terms: D018501:Antirheumatic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage / Q000009:adverse effects*; D007876:Legionellosis / Q000175:diagnosis*; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D009894:Opportunistic Infections / Q000175:diagnosis*; D018124:Receptors, Tumor Necrosis Factor / Q000008:administration & dosage; D012307:Risk Factors; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000068800:Etanercept; D008727:Methotrexate